Shuhui Dong

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

LILRB2+ monocytes reshape the immune activation landscape in immunotherapy with non-small cell lung cancer: Evidence from real-world cohorts and single-cell analyses.

LILRB2+ monocytes reshape the immune activation landscape in immunotherapy with non-small cell lung cancer: Evidence from real-world cohorts and single-cell analyses.

Journal: International journal of biological macromolecules

Published: January 09, 2026

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.

Journal: Cancer immunology, immunotherapy : CII

Published: September 09, 2025

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

Journal: BMC medicine

Published: August 15, 2024

Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.

Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.

Journal: Clinical and translational medicine

Published: May 09, 2024

A subgroup analysis of locally advanced nasopharyngeal carcinoma patients with small lymph nodes and large nodes using adaptive radiotherapy.

A subgroup analysis of locally advanced nasopharyngeal carcinoma patients with small lymph nodes and large nodes using adaptive radiotherapy.

Journal: BMC cancer

Published: March 26, 2024

Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.

Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.

Journal: Oral oncology

Published: March 21, 2024

Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors.

Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors.

Journal: Cancer management and research

Published: January 22, 2024

Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients.

Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients.

Journal: Critical reviews in oncology/hematology

Published: May 18, 2023

Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy.

Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy.

Journal: Scientific reports

Published: May 17, 2023

Showing 1-9 of 9

Last Updated: 09/26/2026